title: A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
authors.forename: T M
authors.initials: TM
authors.lastname: Richards
authors.forename: P N
authors.initials: PN
authors.lastname: Plowman
authors.forename: R
authors.initials: R
authors.lastname: Reznek
authors.forename: S A
authors.initials: SA
authors.lastname: Ball
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008113:Liver Neoplasms / Q000556:secondary*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib